Stocktoria
LABCORP HOLDINGS INC. LH
NYSE · stock · Services-Medical Laboratories · website · IPO 1991-04-24
LABCORP HOLDINGS INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.0B | $13.0B | $12.2B | $11.9B | $13.1B | $14.0B | $11.6B | $11.3B | $10.3B | $9.6B |
| Gross profit | $4.0B | $3.6B | $3.4B | $3.7B | $5.0B | $5.0B | $3.3B | $3.2B | $3.1B | $2.9B |
| SG&A expense | $2.2B | $2.2B | $2.0B | $1.8B | $1.7B | $1.7B | $1.6B | $1.6B | $1.5B | $1.3B |
| Operating income | $1.4B | $1.1B | $725.6M | $1.4B | $3.0B | $2.4B | $1.3B | $1.3B | $1.3B | $1.3B |
| Interest expense | $224.1M | $208.3M | $199.6M | $179.8M | $211.8M | $207.4M | $240.7M | $244.2M | $235.1M | $219.1M |
| Income tax | $229.8M | $212.4M | $188.5M | $233.9M | $690.0M | $662.1M | $280.0M | $384.4M | -$155.4M | $360.7M |
| Net income | $876.5M | $746.0M | $418.0M | $1.3B | $2.4B | $1.6B | $823.8M | $883.7M | $1.2B | $711.8M |
| EPS (diluted) | $10.46 | $8.84 | $4.77 | $13.97 | $24.39 | $15.88 | $8.35 | $8.61 | $11.81 | $6.82 |
| Operating cash flow | $1.6B | $1.6B | $1.3B | $2.0B | $3.1B | $2.1B | $1.4B | $1.3B | $1.5B | $1.2B |
| Free cash flow | $1.2B | $1.1B | $874.1M | $1.5B | $2.7B | $1.8B | $1.0B | $925.6M | $1.2B | $918.2M |
| Cash & equivalents | $532.3M | $1.5B | $536.8M | $320.6M | $1.5B | $1.3B | $337.5M | $426.8M | $316.6M | $433.6M |
| Inventory | $534.7M | $493.2M | $474.6M | $470.6M | $401.4M | $423.2M | $244.7M | $237.3M | $227.2M | $205.2M |
| Total assets | $18.4B | $18.4B | $16.7B | $20.2B | $20.4B | $20.1B | $18.0B | $16.2B | $16.7B | $14.2B |
| Total liabilities | $9.8B | $10.3B | $8.8B | $10.0B | $10.1B | $10.6B | $10.5B | $9.2B | $9.8B | $8.7B |
| Shareholders' equity | $8.6B | $8.1B | $7.9B | $10.1B | $10.3B | $9.4B | $7.6B | $7.0B | $6.8B | $5.5B |
Growth · year-over-year · Revenue CAGR 4.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +7.2% | +7.0% | +2.5% | -9.7% | -6.0% | +21.0% | +2.0% | +9.9% | +7.9% | +10.1% |
| Net income growth | +17.5% | +78.5% | -67.3% | -46.2% | +52.8% | +88.9% | -6.8% | -28.0% | +72.4% | +62.7% |
| EPS growth | +18.3% | +85.3% | -65.9% | -42.7% | +53.6% | +90.2% | -3.0% | -27.1% | +73.2% | +56.8% |
| Free cash flow growth | +10.0% | +25.4% | -42.7% | -43.2% | +53.3% | +67.9% | +12.8% | -21.9% | +29.1% | +26.4% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.